Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Clinical trial NCT06363734 · RECRUITING
Trial details
- NCT number
- NCT06363734
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-09
- Primary completion
- 2025-12-15
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.